The detection of homologous recombination deficiency (HRD) tumors lies in the potential benefit from DNA-damage repair (DDR) targeted agents, however, their efficacy outside the context of BRCA1 and BRCA2 mutations is still under investigation. Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.